Finch Therapeutics Group (NASDAQ:FNCH) Upgraded by Zacks Investment Research to Hold

Finch Therapeutics Group} stock has undergone multiple analysts rating changes in the recent past.  Finch Therapeutics Group Upgraded by Zacks Investment Research on 10/12/2021. In a note to investors, the firm issued a new rating of Hold. The analysts previously had rating of Sell.

View More Finch Therapeutics Group (NASDAQ:FNCH) Upgraded by Zacks Investment Research to Hold